NCT02840994View on ClinicalTrials.gov

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
BIOLOGICAL

CV301

BIOLOGICAL

Pembrolizumab

BIOLOGICAL

Nivolumab

Trial Locations (7)

20892

NCI, Bethesda

27103

Novant Health Oncology Specialists, Winston-Salem

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

46260

Investigative Clinical Research of Indiana, Indianapolis

63110

Washington University School of Medicine, St Louis

70006

Metairie Oncologist, LLC, Metairie

77090

Millennium Oncology, Houston

Sponsors

Lead Sponsor

Bavarian Nordic
All Listed Sponsors
lead

Bavarian Nordic

INDUSTRY

NCT02840994 - A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter